Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

We describe the application of infrared nanospectroscopy and high-resolution atomic force microscopy to visualize the process of protein self-assembly into oligomeric aggregates and amyloid fibrils, which is closely associated with the onset and development of a wide range of human neurodegenerative disorders.

Abstract

The phenomenon of protein misfolding and aggregation results in the formation of highly heterogeneous protein aggregates, which are associated with neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. In particular low molecular weight aggregates, amyloid oligomers, have been shown to possess generic cytotoxic properties and are implicated as neurotoxins in many forms of dementia. We illustrate the use of methods based on atomic force microscopy (AFM) to address the challenging task of characterizing the morphological, structural and chemical properties of these aggregates, which are difficult to study using conventional structural methods or bulk biophysical methods because of their heterogeneity and transient nature. Scanning probe microscopy approaches are now capable of investigating the morphology of amyloid aggregates with sub-nanometer resolution. We show here that infrared (IR) nanospectroscopy (AFM-IR), which simultaneously exploits the high resolution of AFM and the chemical recognition power of IR spectroscopy, can go further and enable the characterization of the structural properties of individual protein aggregates, and thus offer insights into the aggregation mechanisms. Since the approach that we describe can be applied also to the investigations of the interactions of protein assemblies with small molecules and antibodies, it can deliver fundamental information to develop new therapeutic compounds to diagnose or treat neurodegenerative disorders.

Introduction

Over 40 million people worldwide are currently affected by neurodegenerative disorders, such as Alzheimer’s (AD)1 and Parkinson’s (PD)2 diseases. More generally, more than fifty pathologies are associated at the molecular level with protein misfolding and aggregation, a process that leads to the proliferation of insoluble fibrillar protein aggregates, known as amyloid deposits3,4. The molecular origins of neurodegeneration and its links with protein conformational changes of proteins leading to amyloid formation, however, remain unclear, in large part....

Protocol

1. Aggregation assays on fluorescence plate readers

NOTE: The protocol described here is an example of how to study the aggregation of any protein or peptide by chemical kinetics. In particular, it describes an optimized protocol to study the aggregation of the Aβ42 peptide, which is involved in the onset and progression of Alzheimer’s disease58,59. A similar protocol can be adjusted and adopted towards studying the aggregatio.......

Representative Results

A representative time course of Aβ42 aggregation, as measured by the ThT fluorescence assay, is shown in Figure 1. The aggregation process is commonly characterized by a sigmoidal curve, where a lag phase is initially observed, and is followed by a steep growth phase, before the curve reaches a plateau when an equilibrium steady state is reached6,7,58. It is essential to ensure that an optimize.......

Discussion

The first critical step in this protocol is the preparation of monomeric proteins, such as in the case of Aβ42 solution described in steps 1.1 and 1.2. It is essential to initiate the aggregation process from a highly pure, monomeric solution, as the presence of oligomeric or aggregated species may result in poor reproducibility of the aggregation kinetics58, and induce artefacts in the AFM measurements (e.g., fibrillar species will be evident at the initial stages of the aggregation), which .......

Acknowledgements

The authors thank Swiss National Foundation for Science (SNF) for the financial support (grant number P2ELP2_162116 and P300P2_171219), the Darwin College, Erasmus+ program for the financial support (grant number 2018-1-LT01-KA103-046719-15400-P3) and the research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) through the ERC grant PhysProt (agreement number 337969), the Newman Foundation (T.P.J.K.) and The Cambridge Centre for Misfolding Diseases (C.G., M.V., and T.P.J.K.).

....

Materials

NameCompanyCatalog NumberComments
AFM-IR systemAnasys InstrumentsnanoIR 2 or 3Systems to measure thermal expansion in contact and resonance mode
Corning 96-well Half Area Black/Clear Bottom Polystyrene NBS MicroplateCorning3881
Corning Microplate Aluminium Sealing TapeCorning6570
Double Sided Adhesive DiscsAGAR ScientificAGG3347N
FLUOstar OmegaBMG Labtech415-101Platereader
Mica Disc 10mm V1AGAR ScientificAGF7013
Park NX10 AFM systemPark SystemsN/AAtomic Force Microscope
Platypus Ultra-Flat Gold ChipsPlatypus TechnologiesAU.1000.SWTSG
PPP-NCHR-10 cantileversPark SystemsPPP-NCHR-10
Protein LowBind Tubes, 2.0mLEppendorf30108132
Silicon gold coated cantileversAnasys InstrumentsPR-EX-nIR2
SPM Specimen Discs 12mmAGAR ScientificAGF7001

References

  1. Selkoe, D. J., Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine. 8, 595-608 (2016).
  2. Poewe, W., et al. Parkinson disease. Nature Reviews Disease Primers. 3, 1-21 (2017).
  3. <....

Explore More Articles

Protein AggregatesInfrared NanospectroscopyAtomic Force MicroscopySingle Molecule MethodsBiomolecular ProcessesNano ScaleHeterogeneous SystemsProtein AggregationBiomaterialsDrug DeliveryAFM ParametersAFM ImagingAFM CantileverAFM Laser BeamAFM Deflected BeamAFM OscillationAFM Resonance

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved